In its third quarter financial results, the company revealed the medication could cost $15,900.
The medication was approved by the FDA on Aug. 4 and has been touted as a promising treatment for 500,000 mothers who develop the condition each year. However, the cost could put it out of reach for many under-insured or uninsured patients.
Now, as Sage Therapeutics and partner Biogen gear up for the commercial launch of the medication, which should be available in December, the two are in talks with insurance companies to flesh out coverage plans for it, CNN reported.
Sage Therapeutics CEO Barry Greene said in its Q3 financial report that the goal is “to enable broad and equitable access for women with PPD who are prescribed this drug.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
